Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine

Therapeutic Drug Monitoring

Volumn 23, Issue 3, 2001, Pages 255-258

  Van Heeswijk, Rolf P G ^a,d   Veldkamp, Agnes I ^a   Mulder, Jan Willem ^a   Meenhorst, Pieter L ^a   Beijnen, Jos H ^a   Lange, Joep M A ^b,c   Hoetelmans, Richard M W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b Natl AIDS Therapy Evaluation Centre   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Nevirapine; Pharmacokinetics; Saliva; Therapeutic drug monitoring

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ALPRAZOLAM; ATENOLOL; CETIRIZINE; CHLORTALIDONE; COTRIMOXAZOLE; DIAZEPAM; DICLOFENAC; DIDANOSINE; EBASTINE; FLUCONAZOLE; FLURAZEPAM; FLUTICASONE; INDINAVIR; LAMIVUDINE; LORATADINE; MEBEVERINE; MIDAZOLAM; MORPHINE; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STEADY STATE;

ADULT; DRUG MONITORING; FEMALE; HUMANS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SALIVA;

EID: 0035006362     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200106000-00012     Document Type: Article

References (11)

1. Veldkamp AI, Hoetelmans RMW, Beijnen JH, et al. High exposure to nevirapine is associated with a higher initial HIV-1 clearance rate, a higher likelihood to reach undetectability and prolonged suppression of HIV-1 replication. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, Portugal, October 1999 (abstract 239).
2. Joshi AS, Barret JS, Fiske WD, et al. Population pharmacokinetics of efavirenz in phase II studies and relationships with efficacy. 39th Interscience Conference on Antimicrob Agents Chemother, San Francisco, CA, U.S.A., September 1999 (abstract A113).
3. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-107.
4. Liu H, Delgado MR. Therapeutic drug monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 1999;36: 453-70.
5. Kurowski M, Wintergerst U, Müller M, et al. Relation of saliva and plasma levels in patients treated with ritonavir and indinavir. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, Portugal, October 1999 (abstract 833).
6. Hugen PWH, Burger DM, de Graaff M, et al. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit 2000;22:437-45.
7. Gorodischer R, Burtin P, Hwang P, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parenteral preferences and an economic analysis. Ther Drug Monit 1994;16:437-43.
8. Baron S, Poast J, Cloyd MW. Why is HIV rarely transmitted by oral secretions? Arch Intern Med 1999;159:303-10.
9. Van Heeswijk RPG, Hoetelmans RMW, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998;713:395-9.
10. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics, 4th ed. Philadelphia: Lea & Febiger, 1991:14-23.
11. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.